XenoPort (XNPT) and Astellas Pharma Announce an Application for RLS Treatment XP13512 Filed with PMDA in Japan
More News related to XNPT
- XenoPort (XNPT) Said FDA Moves PDUFA Date Due to February 11
- XenoPort Announces Extension of the Horizant(TM) PDUFA Date to February 11, 2010
- XenoPort (XNPT) February put volatility at 138 into FDA deadline
- XenoPort (XNPT) to Name RLS Treatment GSK1838262/XP13512 as Horizant
- XenoPort Announces Horizant(TM) as Brand Name for XP13512
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
Astellas Pharma Inc. and XenoPort, Inc. (NASDAQ: XNPT) today announced that a new drug application (NDA) has been filed with the Pharmaceuticals and Medical Device Agency (PMDA) in Japan for ASP8825 (gabapentin enacarbil), also known as XP13512, as a potential treatment for restless legs syndrome (RLS). The data supporting safety and efficacy in the NDA filing comes from the successful Phase 2 study in RLS patients and long-term safety study conducted by Astellas in Japan and the RLS clinical program conducted by XenoPort in the United States. The acceptance of filing of the NDA triggers a $5 million milestone payment from Astellas to XenoPort.
"We are pleased to submit the NDA for ASP8825 in Japan," said Masafumi Nogimori, Astellas' president and chief executive officer. "We look forward to delivering this new treatment to patients suffering from RLS in Japan."
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
